A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for ...

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA ...

Number 5: Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of ...

Between congressional hearings and executive orders, experts had plenty to draw on when dissecting the barriers to biosimilar ...

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to ...

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 ...

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...